Download PDF
Hamostaseologie
DOI: 10.1055/a-2159-8767
Original Article

Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms

Kai Wille   *
1   University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
,
Eva Deventer   *
1   University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
,
Parvis Sadjadian
1   University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
,
Tatjana Becker
1   University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
,
Vera Kolatzki
1   University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
,
Karlo Hünerbein
1   University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
,
Raphael Meixner
2   Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany
,
Marina Jiménez-Muñoz
2   Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany
,
Christiane Fuchs
2   Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany
3   Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany
,
Martin Griesshammer
1   University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
› Author Affiliations Funding No funding was committed for this study.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Arterial (ATE) and venous (VTE) thromboembolic complications are common causes of morbidity and mortality in BCR-ABL-negative myeloproliferative neoplasms (MPNs). However, there are few studies that include all MPN subtypes and focus on both MPN-associated ATE and VTE. In our single-center retrospective study of 832 MPN patients, a total of 180 first thromboembolic events occurred during a median follow-up of 6.6 years (range: 0–37.6 years), of which 105 were VTE and 75 were ATE. The probability of a vascular event at the end of the follow-up period was 36.2%, and the incidence rate for all first ATE/VTE was 2.43% patient/year. The most frequent VTE localizations were deep vein thrombosis with or without pulmonary embolism (incidence rate: 0.59% patient/year), while strokes were the most frequent ATE with an incidence rate of 0.32% patient/year. When comparing the group of patients with ATE/VTE (n = 180) and the group without such an event (n = 652) using multivariate Cox regression analyses, patients with polycythemia vera (hazard ratio [HR]: 1.660; [95% confidence interval [CI] 1.206, 2.286]) had a significantly higher risk of a thromboembolic event than the other MPN subtypes. In contrast, patients with a CALR mutation had a significantly lower risk of thromboembolism compared with JAK2-mutated MPN patients (HR: 0.346; [95% CI: 0.172, 0.699]). In summary, a high incidence of MPN-associated VTE and ATE was observed in our retrospective study. While PV patients or generally JAK2-mutated MPN patients had a significantly increased risk of such vascular events, this risk was reduced in CALR-mutated MPN patients.

Keywords

arterial thrombosis - deep vein thrombosis - management of disease - venous thrombosis

Availability of Data and Materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.


Ethical Approval

The questionnaire and study protocol for this retrospective study were approved by the Ethics Committee of the Ruhr-Universität Bochum, based in Bad Oeynhausen.


Consent to Participate

Written consent was obtained from all individual participants included in the study.


Code Availability

Not applicable.


* Both authors contributed equally to this work.




Publication History

Received: 02 May 2023

Accepted: 24 August 2023

Article published online:
09 October 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Tefferi A, Rumi E, Finazzi G. et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27 (09) 1874-1881
    CrossrefPubMedGoogle Scholar
  • 2 Hultcrantz M, Wilkes SR, Kristinsson SY. et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol 2015; 33 (20) 2288-2295
    CrossrefPubMedGoogle Scholar
  • 3 Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22 (01) 14-22
    CrossrefPubMedGoogle Scholar
  • 4 Carobbio A, Thiele J, Passamonti F. et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117 (22) 5857-5859
    CrossrefPubMedGoogle Scholar
  • 5 Barbui T, Carobbio A, Rumi E. et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 2014; 124 (19) 3021-3023
    CrossrefPubMedGoogle Scholar
  • 6 Baigent C, Blackwell L, Collins R. et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678) 1849-1860
    CrossrefPubMedGoogle Scholar
  • 7 Bertozzi I, Bogoni G, Biagetti G. et al. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol 2017; 96 (08) 1297-1302
    CrossrefPubMedGoogle Scholar
  • 8 Pei YQ, Wu Y, Wang F, Cui W. Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Ann Hematol 2016; 95 (09) 1391-1398
    CrossrefPubMedGoogle Scholar
  • 9 Barbui T, Finazzi G, Carobbio A. et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120 (26) 5128-5133 , quiz 5252
    CrossrefPubMedGoogle Scholar
  • 10 Harrison CN, Campbell PJ, Buck G. et al; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353 (01) 33-45
    CrossrefPubMedGoogle Scholar
  • 11 Landolfi R, Marchioli R, Kutti J. et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350 (02) 114-124
    CrossrefPubMedGoogle Scholar
  • 12 Barbui T, Carobbio A, Cervantes F. et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115 (04) 778-782
    CrossrefPubMedGoogle Scholar
  • 13 Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol 2012; 25 (03) 235-242
    CrossrefPubMedGoogle Scholar
  • 14 Rothwell PM, Coull AJ, Silver LE. et al; Oxford Vascular Study. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366 (9499) 1773-1783
    CrossrefPubMedGoogle Scholar
  • 15 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
    CrossrefPubMedGoogle Scholar
  • 16 Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 2013; 162 (06) 730-747
    CrossrefPubMedGoogle Scholar
  • 17 De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 2010; 5 (06) 487-494
    CrossrefPubMedGoogle Scholar
  • 18 Kaifie A, Kirschner M, Wolf D. et al; Study Alliance Leukemia (SAL). Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 2016; 9: 18
    CrossrefPubMedGoogle Scholar
  • 19 Hultcrantz M, Björkholm M, Dickman PW. et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 2018; 168 (05) 317-325
    CrossrefPubMedGoogle Scholar
  • 20 Wille K, Sadjadian P, Becker T. et al. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Ann Hematol 2019; 98 (01) 93-100
    CrossrefPubMedGoogle Scholar
  • 21 De Stefano V, Za T, Rossi E. et al; GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93 (03) 372-380
    CrossrefPubMedGoogle Scholar
  • 22 Koschmieder S. The approach to thrombosis prevention across the spectrum of Philadelphia-negative classic myeloproliferative neoplasms. Hemato 2021; 2: 392-402
    CrossrefPubMedGoogle Scholar